Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin

Karadeniz C., Oguz A., Canter B., Serdaroglu A.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.17, no.7, pp.585-590, 2000 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 7
  • Publication Date: 2000
  • Doi Number: 10.1080/08880010050122852
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.585-590
  • Gazi University Affiliated: No


Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects. Most studies report incidence rates ranging from 1.5 to 3%. There is no study on the incidence rate among children with systemic malignancies. Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2 % of imipenem/cilastatin administrations was followed by a seizure attack.